![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, February 01, 2014 3:00:32 PM
I'm clearly jumping the gun a bit here, but looking at the horizon for potential partners for IDRA in larger autoimmune indications, I keep coming back to Celgene.
1. CELG has experience partnering in the TLR space - see their deal with Venti-RX. http://bit.ly/1nB3G77
2. CELG has been very aggressive and creative in partnering with development stage biotechs, and IDRA - given their unique focus on orphan indications, and thus less need for a huge up-front payment - seems a great fit for a creative deal.
3. CELG is actively looking to expand their autoimmune franchise.
It's just a thought, but I wouldn't be surprised.
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM